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ABSTRACT
Objectives Dyspnoea is one of the symptoms frequently 
encountered after treatment with chemoradiotherapy 
(CRT) in stage III non- small cell lung cancer (NSCLC). 
Long- term data on mild to moderately severe cardiac 
events as underlying cause of dyspnoea in patients with 
stage III NSCLC are lacking. Therefore, the incidence of 
new cardiac events, with a common terminology criteria 
for adverse events (CTCAE) score of ≥2 within 5 years after 
diagnosis, were analysed.
Design Retrospective multicentre cohort study of patients 
with stage III NSCLC treated with CRT from 2006 to 2013. 
The medical files of the treated patients were reviewed.
Outcome measures The primary endpoint of the study 
was the incidence of new cardiac events with a CTCAE 
score of ≥2 within 5 years after diagnosis. Secondary 
endpoint was to identify risk factors associated with the 
development of a cardiac event.
Results Four hundred and sixty patients were included 
in the study. Of all patients, 150 (32.6%) developed a new 
cardiac event. In patients with a known cardiac history 
(n=138), 44.2% developed an event. The most common 
cardiac events were arrhythmia (14.6%), heart failure 
(7.6%) and symptomatic coronary artery disease (6.8%). 
Pre- existent cardiac comorbidity (HR 1.96; p<0.01) and 
WHO- performance score ≥2 (HR 2.71; p<0.01) were 
significantly associated with developing a cardiac event. 
The majority of patients did not have pre- existent cardiac 
comorbidity (n=322). Elevated WHO/International Society 
of Hypertension score was not identified as a significant 
predictor for cardiac events.
Conclusion One- third of patients with stage III NSCLC 
treated in daily clinical practice develop a new cardiac 
event within 5 years after CRT. All physicians confronted 
with patients with NSCLC should take cardiac comorbidity 
as a serious possible explanation for dyspnoea after 
treatment with CRT.
INTRODUCTION
Lung cancer is, next to breast cancer, the 
most common cancer worldwide contributing 
12.3% of the total number of new cases diag-
nosed.1 2 Non- small cell lung cancer (NSCLC) 
is the most frequently diagnosed form of 
lung cancer and approximately one- third of 
all patients with NSCLC present with locally 
advanced, stage III, disease.3 Concurrent 
chemoradiotherapy (cCRT) is the preferred 
treatment with a 5- year overall survival (OS) 
of 25%–35%.4–7 Current treatment methods, 
including CRT with immune modulating 
therapy such as durvalumab has improved 
3- year survival up to 66%.8 9 As survival rates 
are improving, long- term adverse events 
and their potential impact on quality of life 
become more important.8 10
After completing lung cancer treatment, 
patients with stage III NSCLC are monitored 
at the outpatient’s clinic every 3 months in 
the first 2 years and every 6 months in year 
3 to 5.11 In between these consults, patients 
commonly visit their general practitioner 
(GP) with physical complaints possibly related 
to their treatment. Dyspnoea is one of the 
problems frequently encountered and can be 
attributed to radiation- induced pneumonitis 
Strengths and limitations of this study
 ► Large, multicentre, well- defined group of patients 
with stage III non- small cell lung cancer treated ac-
cording to standard clinical care.
 ► All patients’ records have been systematically re-
viewed based on a predetermined strategy.
 ► Because of the retrospective analysis we cannot 
rule out that some cardiac events with common ter-
minology criteria for adverse events score ≥2 were 
missed.
 ► Detailed analysis of dose–volume parameters of ra-
diotherapy were not included in this study.
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or an underlying other primary pulmonary problem such 
as chronic obstructive pulmonary disease. Importantly, 
recent studies have shown that short- term cardiac events 
in NSCLC are common.12–15 Within 24 months after treat-
ment, the reported incidence of serious cardiac adverse 
events was 11%–23% in a pooled analysis of prospective 
dose- escalated radiotherapy trials, where the given radi-
ation dose was higher compared with standard care to 
improve treatment tolerability or maximise treatment 
effects.12–14 This high incidence of cardiac events was 
confirmed in a cohort of stage II and III NSCLC (n=748) 
treated in daily clinical practice showing a cumulative inci-
dence of cardiac events of 23%.15 In these studies, high 
mean radiation dose to the heart was associated with an 
increased risk for development of a serious cardiac event. 
Long- term data on mild to moderately severe cardiac 
events in patients with stage III NSCLC, who are often 
first presented to the GP, are still lacking. Therefore, the 
primary objective of the current study was to analyse the 
5- year cumulative incidence of cardiac events with a mild 
to severe impact in patients with stage III NSCLC, treated 
with CRT in daily clinical care. The secondary objective 
was to identify clinical risk factors for the development of 
a cardiac event in this specific patient cohort.
METHOD
Study design and study subjects
This is a retrospective multicentre cohort study of patients 
with stage III NSCLC treated with cCRT or sequential 
CRT (sCRT). From 2006 to 2013, all consecutive patients 
with NSCLC referred from three different hospitals to 
MAASTRO clinic for radiotherapy, were included in a 
prospective cohort. In retrospect, patients with patho-
logically proven stage III NSCLC were selected from this 
cohort for the current study. A retrospective evaluation 
of treatment and follow- up was performed. This study 
was approved by the internal review board of MAASTRO 
clinic.
Patient and public involvement
Patients and members of the public were not involved in 
the design and conduction of this retrospective study.
Patient file search
A trained physician examined the patient files according 
to a predetermined case report form (CRF). This CRF was 
compiled by a research team of pulmonologists, cardiol-
ogist and radiation oncologist all working in one of the 
three hospitals. The following domains of the patient file 
were reviewed:
General medical history
Comorbidity expressed as the Charlson comorbidity 
index (CCI) which predicts the 10- year mortality based 
on comorbid conditions, use of medication, WHO- 
performance score (WHO- PS) at diagnosis.
Tumour and treatment-specific information
Date of diagnosis of stage III NSCLC, histological type, 
recurrence or progression of diagnosed stage III disease 
and chemotherapy treatment.
Cardiac risk profile based on age, gender, blood pressure, smoking 
and diabetes status
For each patient the baseline WHO/International Society 
of Hypertension (WHO/ISH) score for predicting the 
10- year risk of a fatal or non- fatal major cardiovascular 
event (myocardial infarction or stroke) were documented 
according to age, gender, blood pressure, smoking history 
and diabetes status.
Pre-existing cardiac comorbidity
Pre- existent treatment of arrhythmia, coronary artery 
disease, pericardial disease, heart failure or cardiomyop-
athy not otherwise specified (NOS).
Development of cardiac events within 5 years after the diagnosis 
NSCLC
All cardiac events developed within 5 years after the diag-
nosis of NSCLC were documented. Both pre- existent and 
new cardiac events were classified according to common 
terminology criteria for adverse events (CTCAE score, 
V.4.0). A cardiac event was included in the analysis if 
there was (sub)acute need for medical intervention, 
which corresponds to a CTCAE ≥2. In case of more than 
one cardiac event, the event with the most impact on 
morbidity (highest CTCAE score) was included.
The research team defined five different cardiac events:
1. Arrhythmia: symptomatic atrial or ventricular arrhyth-
mia requiring medical or procedural intervention.
2. Coronary artery disease: chest pain with increased car-
diac biomarkers, abnormal ECG or proven significant 
stenosis on cardiac catheterisation followed by inter-
vention.
3. Pericardial disease: containing both the occurrence of 
pericarditis or non- malignant pericardial effusion con-
firmed by echocardiography or ECG.
4. Heart failure: shortness of breath due to acute or 
chronic heart failure (including valve dysfunction) 
diagnosed by echocardiography or increased cardiac 
blood parameters.
5. Cardiomyopathy NOS: cardiac resuscitation and car-
diomyopathy NOS.
Treatment of NSCLC
All patients were treated with CRT. Chemotherapy 
treatment consisted of platinum- based therapy with 
gemcitabine, etoposide or vinorelbine combined with 
radiotherapy according to the treatment guidelines in 
the period 2006–2013 in the Netherlands. The median 
prescribed dose of radiotherapy was 60–65 Gy delivered 
in 30 fractions of 1.5 Gy in two fractions per day, followed 
by one fraction a day of 2 Gy for 2 weeks until organ 
tolerance was reached. All patients with stage III NSCLC 
were treated with intensity- modulated radiation therapy 
(IMRT) from 2009 onwards. In that period, the pursued 
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dose–volume constraints for the heart was a mean heart 
dose of <45 Gy, reflecting the prevailing opinion that 
cardiac side effects were not that important in this popula-
tion for they were presumed to occur after many decades, 
analogous to patients with Hodgkin’s disease.16
Statistics
Descriptive statistics of demographic and clinical vari-
ables were obtained. Competing risk analysis was used 
to analyse the cumulative incidence of all CTCAE ≥2 
cardiac events corrected for the competing risk of death. 
To assess the contribution of different clinical factors to 
the development of a cardiac event, cox regression anal-
ysis was performed by including potential contributing 
factors in the multivariate analysis, identified as factors 
yielding a p value <0.30 in univariate analysis. Results with 
two- sided exact p values (≤0.05) were considered statis-
tically significant. A proportional hazard model for the 
competing risk analysis was performed using R software. 
All other analyses were performed using SPSS statistical 
software, V.24.0.
RESULTS
Patient characteristics
Four hundred and sixty patients were included in the 
study (figure 1). Baseline patient characteristics are 
shown in table 1.
Cardiac events
Within 5 years after treatment, 150 (32.6%) patients 
developed cardiac event (CTCAE ≥2). The following 
cardiac events were observed: arrhythmia (n=68, 14.7%), 
symptomatic coronary artery disease (n=30, 6.5%), heart 
failure (n=33, 7.2%), symptomatic pericardial disease 
(n=13, 2.8%) and six (1.3%) patients were brought into 
the emergency room because of cardiomyopathy NOS 
(cardiopulmonary resuscitation). Of all patients, 45 
(9.8%) developed more than one event. Ninety- three 
(62%) events occurred in the first year after diagnosis. 
The incidence of cardiac events after 18 and 24 months 
was respectively 23.3% (107 events) and 26% (120 
Figure 1 CONSORT diagram (n=460). CRT, 
chemoradiotherapy; cCRT, concurrent chemoradiotherapy 
CONSORT, Consolidated Standards of Reporting Trials; 
NSCLC, non- small cell lung cancer; RT, radiotherapy; sCRT, 
sequential CRT.
Table 1 Patient characteristics (n=460)
N %
Male gender 274 59.6
Age (mean, range) 65.2 (32–88)
WHO- PS*
  0 290 63
  1 135 29.3
  ≥2 35 7.6
Comorbidity index†
  Low (0–3) 155 33.7
  Intermediate (4–6) 234 50.9
  High (7–9) 71 15.4
WHO/ISH risk score‡
  Low (<10%) 227 49.3
  High (>10%) 177 38.5
  Unknown 56 12.2
Treatment‡
  cCRT 391 85
  sCRT 69 15
Radiotherapy§
  3D- CRT 67 14.6
  IMRT 393 85.4
Chemotherapy
  Combined cisplatine 311 67.6
  Combined carboplatine 127 27.6
  Otherwise/unknown 22 4.8
Cardiac risk profile
  Smoker (active/former) 185/200 40.2/43.5
  Hypertension, yes 124 27
  Diabetes mellitus, yes 66 14.3
  Statin use, yes 118 25.7
Pre- existing cardiac comorbidity 138 30
  Arrhythmia 37 8
  Symptomatic coronary artery disease 61 13.3
  Pericardial disease 6 1.3
  Heart failure 21 4.6
  Cardiomyopathy NOS§ 13 2.8
*WHO- PS: quantifies general well- being and activities of daily life of patients 
with cancer.
†CCI: prediction of the 10- year survival in patients with multiple 
comorbidities.
‡WHO/ISH risk prediction score: indicates 10- year risk of a fatal or non- fatal 
major cardiovascular event according to age, sex, blood pressure, smoking 
status and diabetes mellitus status.
§Cardiomyopathy NOS: cardiac resuscitation and cardiomyopathy NOS.
CCI, Charlson comorbidity index; cCRT, concurrent chemoradiotherapy; 
3D- CRT, three- dimensional conformal radiation therapy; IMRT, intensity- 
modulated radiation therapy; ISH, International Society of Hypertension; 
NOS, not otherwise specified; sCRT, sequential CRT; WHO- PS, WHO- 
performance score.
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events). The median time to worst cardiac event was 9 
months (mean 13.6; SD 14.5; range 0–60 months). There 
was no significant difference in the number of cardiac 
events between patients treated with cCRT or sCRT. 
Details on all cardiac events are shown in table 2. The 
overall cumulative incidence of a cardiac event corrected 
for the competing risk of death is shown in figure 2.
Clinical risk factors
On univariate analysis, male gender, age ≥70, high 
WHO- PS ≥2, high CCI score of 7–9, use of statins which 
reflex hypercholesterolaemia and pre- existent cardiac 
comorbidity were significantly associated with the devel-
opment of a new cardiac event within 5 years. However, 
on multivariate analysis only pre- existent cardiac comor-
bidity (HR 1.96; 95% CI 1.29 to 2.98; p<0.01) and WHO- PS 
≥2 (HR 2.71; 95% CI 1.33 to 5.52; p<0.01) were indepen-
dent significant predictors for a cardiac event (table 3).
Subgroup analysis
Pre-existent cardiac comorbidity
In the subgroup of patients with a cardiac history (n=138, 
30%), 61 (44.2%) patients developed a new cardiac 
event during follow- up. On univariate analysis, WHO- PS 
≥2 and cisplatin- based treatment were significantly asso-
ciated with the development of a new cardiac event. On 
multivariate analysis both factors remained significantly 
risk factors (HR 3.77; 95% CI 1.12 to 12.70; p=0.032 and 
HR 2.85; 95% CI 1.36 to 5.98; p=0.006, respectively; 
table 4). The median time to worst cardiac event was 7 
months (mean 12.3±12.7 months). The incidence of 
cardiac events in this group after 12, 18 and 24 months 
was respectively 43 (31.2%), 46 (33.3%) and 51 (37%).
No pre-existent cardiac comorbidity
The majority of patients did not have pre- existent cardiac 
comorbidity (n=322, 70%). Of these patients, 33% had 
an elevated risk (>10%) to develop a serious cardiac 
event according to the WHO/ISH risk chart. Eighty- nine 
(27.6%) patients developed a cardiac event. Neverthe-
less, univariate analysis did not identify a high WHO/
ISH score as a significant predictor for a cardiac event. 
No other clinical factor was significantly associated with 
the development of a cardiac event. The median time 
to worst cardiac event was 11 months (mean 15.0±15 
months). The incidence of cardiac events after 12, 18 and 
Table 2 Survival and new cardiac events (n=460)
N %
5- year survival 118 25.7
New cardiac events <5 years, CTCAE ≥2*
  Yes 150 32.6
Type cardiac event
  Arrhythmia 68 14.7
  Symptomatic coronary artery 
disease
30 6.5
  Pericardial disease 13 2.8
  Heart failure 33 7.2
  Cardiomyopathy NOS† 6 1.3
Overall time to event, months (median, 
range)
9 (0–60)
>1 cardiac event 45 9.8
*The severity of the event was graded using the CTCAE V.4.0.
†Cardiomyopathy NOS: cardiac resuscitation and cardiomyopathy 
NOS.
CTCAE, common terminology criteria for adverse events; NOS, not 
otherwise specified.
Figure 2 Cumulative incidence corrected for the competing risk of death.
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24 months in this group was respectively 50 (15.5%), 61 
(18.9%) and 69 (21.4%).
Survival
All patients were followed for at least 5 years or until 
death. The 5- year survival rate was 25.7% with a median 
OS of 23 months (95% CI 20.5 to 25.5). In univariate 
cox regression analysis age ≥70 years (HR=1.71; 95% CI 
1.08 to 2.71, p=0.02) and WHO- PS ≥2 (HR=3.96; 95% CI 
1.19 to 13.17, p=0.025) were significantly associated with 
survival. The development of a cardiac event was not of 
significant influence. Twenty- three (5%) patients died of 
a fatal cardiac event. However, this number could be an 
underestimation because in 78 (17%) of the patients the 
precise cause of death was unknown.
DISCUSSION
To our knowledge, this study is the first to analyse the 
5- year follow- up of cardiac comorbidity and cardiac 
events in patients with stage III NSCLC treated with CRT 
in routine clinical practice, taking into account cardiac 
dose constraints. Our results show that cardiac events 
are a highly prevalent, under- reported problem. This 
renders our dataset relevant to all physicians confronted 
with patients with NSCLC post CRT, especially GPs as 
they are usually the first point of contact for patients. Of 
all patients, 150 (32.6%) developed a new cardiac event 
with a median time to worst cardiac event of 9 months 
(mean 13.6; SD 14.5; range 0–60 months). The most 
common cardiac events were arrhythmia (14.6%), 
heart failure (7.6%) and symptomatic coronary artery 
disease (6.8%). Pre- existent cardiac comorbidity and 
WHO- PS ≥2 were significantly associated for developing 
a new cardiac event. Our results show that 62% of all 
cardiac events develop within the first 12 months after 
diagnosis. In patients with pre- existent cardiac comor-
bidity, WHO PS ≥2 and treatment with cisplatin- based 
therapy during CRT was significantly associated with the 
development of a cardiac event. In patients without a 
pre- existent cardiac history, high WHO/ISH score was 
not significantly associated with the development of a 
cardiac event.
Table 3 Univariate and multivariate analysis (n=460)
Covariate
Univariate analysis Multivariate analysis
HR
95% CI
P value N HR
95% CI
P valueLower Upper Lower Upper
Male gender 1.56 1.04 2.35 0.03 274
Age (≥70 year) 1.54 1.03 2.30 0.04 165
WHO- PS (≥2)* 3.03 1.50 6.10 0.04 35 2.71 1.33 5.52 <0.01
CCI†
  High (7–9) 2.50 1.39 4.0 <0.01 71
Pre- existing cardiac comorbidity, yes 2.07 1.37 3.14 <0.01 138 1.96 1.29 2.98 <0.01
Statin use, yes 1.61 1.04 2.48 0.03 118
WHO 10- year risk of serious cardiac event‡
  >10% 0.95 0.63 1.44 0.81 177
*WHO- PS: quantifies general well- being and activities of daily life of patients with cancer.
†CCI: prediction of the 10- year survival in patients with multiple comorbidities.
‡WHO/ISH risk prediction score: indicates 10- year risk of a fatal or non- fatal major cardiovascular event according to age, sex, blood 
pressure, smoking status and diabetes mellitus status.
CCI, Charlson comorbidity index; WHO/ISH, WHO/International Society of Hypertension; WHO- PS, WHO- performance score.
Table 4 Univariate and multivariate analysis of pre- existing cardiac comorbidity (n=138)
Covariate
Univariate analysis Multivariate analysis
HR
95% CI
P value N HR
95% CI
P valueLower Upper Lower Upper
WHO- PS (≥2)* 4.90 1.50 16.10 <0.01 17 3.80 1.10 12.70 0.03
Type of platinum- based therapy, first line
  Cisplatin 3.30 1.60 6.80 <0.01 73 2.80 1.40 5.90 <0.01
  Carboplatin 1.60 0.30 7.9 0.50 58
*WHO- PS: quantifies general well- being and activities of daily life ofpatients with cancer.
WHO- PS, WHO- performance score.
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To reflect daily clinical practice, we chose to include 
all cardiac events with a CTCAE score of ≥2 to investi-
gate the mild to severe impact and incidence of cardiac 
events. Our results show that most cardiac events 
develop in the first year after diagnosis. Comparable 
to previous studies, arrhythmias, which often present 
with dyspnoea and decreased exercise tolerance, were 
the most frequently observed cardiac events in the first 
year after diagnosis.13 The incidence of arrhythmias in 
the current study population is remarkably higher than 
expected in this age group based on a Dutch popula-
tion based prospective cohort study.17 The 5- year cumu-
lative risk for developing atrium fibrillation was 2.8% 
in men and 2.0% in women at the age of 65 compared 
with an incidence of 14.7% in the current study. The 
incidence of cardiac events described in the current 
study is comparable with previous published numbers 
by Billiet et al.18 Here, stage III NSCLC had undergone 
surgical resection and if necessary, were treated with 
postoperative radiotherapy. The incidence of different 
cardiac events were comparable between the two patient 
groups and the results of the current study, emphasising 
that the development of cardiac events is associated 
with individual risk factors and not only correlated with 
specific treatment.
Seventy percent of the study population had a negative 
history for cardiac comorbidity. Nevertheless, 27.6% of 
these patients developed a cardiac event. In this group, 
we could not identify a risk factor for developing a cardiac 
event. Similar to other studies, no significant associa-
tion between the WHO/ISH score, which is often used 
to assess cardiovascular risk, and the development of a 
cardiac event was found.13
The OS was not significantly influenced by the devel-
opment of cardiac events in this cohort. However, predic-
tion models for survival in lung cancer showed that a large 
lung tumour, active smoking during therapy and high 
radiation dose to the heart are predictive for mortality.19
The main strength of our study comes from a large, 
multicentre, well- defined, group of consecutive patients 
with stage III NSCLC, who were treated according to 
the standard clinical care. All patients’ records have 
been systematically reviewed based on a predetermined 
search strategy. Therefore, we believe that our results are 
representative for daily clinical practice. Because of the 
retrospective analysis of cardiac events, we cannot rule 
out that some cardiac events with CTCAE score ≥2 were 
missed. Therefore, our results could be an underestima-
tion of the total amounts of cardiac events in our popu-
lation. Previous studies have identified a higher mean 
heart dose as a significant prognostic factor for cardiac 
events.12 13 20 21 However, a detailed analysis of the dose–
volume parameters of radiotherapy in relation to cardiac 
events is beyond the scope of this work and internation-
ally agreed dose constraints were taken into account. 
Because of increased awareness of the cardiac side effects, 
more emphasis has emerged in cardiac sparing radio-
therapy techniques, including IMRT, proton therapy and 
MRI- guided radiotherapy.22 These have resulted in new 
guidelines, which may further decrease toxicity.23
In view of the high prevalence of heart disease in this 
population, we suggest that patients at risk for cardio-
vascular complications, should be seen by a cardiologist 
prior to CRT for optimalisation of their cardiac condition. 
In addition, both the treating clinical physicians and the 
GP should take cardiac comorbidity as a serious possible 
explanation for dyspnoea after treatment with CRT. So, 
patients with unexplained complaints during or post 
treatment should be referred for screening of cardiovas-
cular disease, with emphasis on cardiovascular events with 
high incidence as described in this study such as heart 
failure or arrhythmias. Nevertheless, future research has 
to reveal whether screening and treatment for cardiac 
comorbidity before start of treatment will diminish the 
incidence of mild to severe cardiac events in patients with 
stage III NSCLC.
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